AP658A - Cisapride extended release oral compositions. - Google Patents

Cisapride extended release oral compositions. Download PDF

Info

Publication number: AP658A
Authority: AP; ARIPO
Prior art keywords: cisapride; weight; extended release; mixture; release formulation
Prior art date: 1994-11-02

Application number

APAP/P/1997/000969A

Other languages

English (en)

Other versions

AP9700969A0 (en

Inventor

Eugene Marie Jozef Jans

Paul Marie Victor Gilis

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-02

Filing date

1995-10-25

Publication date

1998-08-17

1995-10-25 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1997-04-30 Publication of AP9700969A0 publication Critical patent/AP9700969A0/xx

1998-08-17 Application granted granted Critical

1998-08-17 Publication of AP658A publication Critical patent/AP658A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 75
238000013265 extended release Methods 0.000 title claims abstract description 18
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 title description 20
229960005132 cisapride Drugs 0.000 title description 20
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 title description 19
238000009472 formulation Methods 0.000 claims abstract description 32
229940095064 tartrate Drugs 0.000 claims abstract description 24
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 11
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
229920000642 polymer Polymers 0.000 claims description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
229920002678 cellulose Polymers 0.000 claims description 8
239000001913 cellulose Substances 0.000 claims description 8
239000004615 ingredient Substances 0.000 claims description 8
239000008101 lactose Substances 0.000 claims description 8
239000000314 lubricant Substances 0.000 claims description 7
208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
238000000034 method Methods 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 2
230000002640 gastrokinetic effect Effects 0.000 abstract 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
239000000454 talc Substances 0.000 description 10
229910052623 talc Inorganic materials 0.000 description 10
235000012222 talc Nutrition 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
229910001868 water Inorganic materials 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
229920001477 hydrophilic polymer Polymers 0.000 description 7
229960001375 lactose Drugs 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
229910002012 Aerosil® Inorganic materials 0.000 description 6
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
239000000945 filler Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000008199 coating composition Substances 0.000 description 3
229920003130 hypromellose 2208 Polymers 0.000 description 3
229940031707 hypromellose 2208 Drugs 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
235000013772 propylene glycol Nutrition 0.000 description 3
YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000005176 gastrointestinal motility Effects 0.000 description 2
229960003943 hypromellose Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-L 2,3-dihydroxybutanedioate Chemical compound [O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-L 0.000 description 1
MNWSGMTUGXNYHJ-UHFFFAOYSA-N 2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(N)=O MNWSGMTUGXNYHJ-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001090 anti-dopaminergic effect Effects 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
-1 for example Polymers 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 1
229920003125 hypromellose 2910 Polymers 0.000 description 1
229940031672 hypromellose 2910 Drugs 0.000 description 1
229920003127 hypromellose 2910 (5 MPa.s) Polymers 0.000 description 1
229960003535 hypromellose 2910 (5 mpa.s) Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003605 opacifier Substances 0.000 description 1
235000020825 overweight Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000002325 prokinetic agent Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cereal-Derived Products (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

APAP/P/1997/000969A 1994-11-02 1995-10-25 Cisapride extended release oral compositions. AP658A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94203184		1994-11-02
PCT/EP1995/004198 WO1996014070A1 (en)	1994-11-02	1995-10-25	Cisapride extended release oral compositions

Publications (2)

Publication Number	Publication Date
AP9700969A0 AP9700969A0 (en)	1997-04-30
AP658A true AP658A (en)	1998-08-17

Family

ID=8217338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1997/000969A AP658A (en)	1994-11-02	1995-10-25	Cisapride extended release oral compositions.

Country Status (29)

Country	Link
US (2)	US6153623A (tr)
EP (1)	EP0789572A1 (tr)
JP (1)	JP3182423B2 (tr)
KR (1)	KR100255521B1 (tr)
AP (1)	AP658A (tr)
AR (1)	AR001765A1 (tr)
AU (1)	AU704284B2 (tr)
BG (1)	BG63244B1 (tr)
BR (1)	BR9509565A (tr)
CA (1)	CA2203663C (tr)
CZ (1)	CZ287844B6 (tr)
EE (1)	EE03510B1 (tr)
FI (1)	FI971856L (tr)
HR (1)	HRP950539A2 (tr)
HU (1)	HUT77887A (tr)
IL (1)	IL115843A0 (tr)
MY (1)	MY113092A (tr)
NO (1)	NO312538B1 (tr)
NZ (1)	NZ295166A (tr)
OA (1)	OA10419A (tr)
PL (1)	PL181470B1 (tr)
RO (1)	RO116042B1 (tr)
RU (1)	RU2143890C1 (tr)
SK (1)	SK54297A3 (tr)
TR (1)	TR199501351A2 (tr)
TW (1)	TW466114B (tr)
UA (1)	UA50721C2 (tr)
WO (1)	WO1996014070A1 (tr)
ZA (1)	ZA959221B (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA959221B (en) *	1994-11-02	1997-04-30	Janssen Pharmaceutica Nv	Cisapride extended release
CA2232489A1 (en) *	1995-12-01	1997-06-12	Janssen Pharmaceutica N.V.	Cisapride sustained release
DE69713948D1 (de) *	1996-04-23	2002-08-22	Janssen Pharmaceutica Nv	Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
EP0951278A2 (en) *	1997-01-03	1999-10-27	ELAN CORPORATION, Plc	Sustained release cisapride mini-tablet formulation
JP2002504107A (ja) *	1997-06-11	2002-02-05	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	（＋）−または（−）−シサプリドの即時放出性ｐＨ非依存的固形投薬剤形
TW407058B (en)	1998-07-17	2000-10-01	Dev Center Biotechnology	Oral cisapride dosage forms with an extended duration
CO5140079A1 (es) *	1998-10-14	2002-03-22	Novartis Ag	Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
EP1169024B1 (en)	1999-03-31	2005-12-21	Janssen Pharmaceutica N.V.	Pregelatinized starch in a controlled release formulation
EP1060743A1 (en) *	1999-06-17	2000-12-20	Development Center For Biotechnology	Oral cisapride dosage forms with an extended duration
CZ20021076A3 (cs) *	1999-09-28	2002-08-14	Panacea Biotec Limited	Prostředky s kontrolovaným uvolňováním obsahující nimesulid
ATE361060T1 (de) *	2000-09-29	2007-05-15	Solvay Pharm Bv	Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
DE60228939D1 (de) *	2002-05-21	2008-10-30	Watson Lab Inc	Pharmazeutische Zusammensetzung mit verzögerter Freisetzung
EP2005946B1 (en)	2006-04-12	2015-11-18	Nippon Soda Co., Ltd.	Method for producing extended release tablet
RU2356532C2 (ru) *	2007-06-01	2009-05-27	Открытое Акционерное Общество "Отечественные Лекарства"	Фармацевтическая композиция проксодолола с контролируемым высвобождением
WO2010099508A1 (en)	2009-02-26	2010-09-02	Theraquest Biosciences, Inc.	Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0076530A2 (en) *	1981-10-01	1983-04-13	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
WO1993018755A1 (en) *	1992-03-25	1993-09-30	Depomed Systems, Incorporated	Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1996014070A1 (en) *	1994-11-02	1996-05-17	Janssen Pharmaceutica N.V.	Cisapride extended release oral compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5057525A (en) *	1981-10-01	1991-10-15	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
EP1145715A3 (en) *	1992-07-07	2004-05-19	Sepracor Inc.	Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders

1995
- 1995-10-13 ZA ZA959221A patent/ZA959221B/xx unknown
- 1995-10-24 TW TW084111217A patent/TW466114B/zh not_active IP Right Cessation
- 1995-10-25 HU HU9702100A patent/HUT77887A/hu unknown
- 1995-10-25 WO PCT/EP1995/004198 patent/WO1996014070A1/en not_active Ceased
- 1995-10-25 EE EE9700105A patent/EE03510B1/xx not_active IP Right Cessation
- 1995-10-25 UA UA97052122A patent/UA50721C2/uk unknown
- 1995-10-25 AU AU38447/95A patent/AU704284B2/en not_active Ceased
- 1995-10-25 PL PL95319948A patent/PL181470B1/pl not_active IP Right Cessation
- 1995-10-25 KR KR1019970702799A patent/KR100255521B1/ko not_active Expired - Fee Related
- 1995-10-25 US US08/817,739 patent/US6153623A/en not_active Expired - Fee Related
- 1995-10-25 AP APAP/P/1997/000969A patent/AP658A/en active
- 1995-10-25 RU RU97108687/14A patent/RU2143890C1/ru not_active IP Right Cessation
- 1995-10-25 JP JP51501196A patent/JP3182423B2/ja not_active Expired - Fee Related
- 1995-10-25 NZ NZ295166A patent/NZ295166A/xx unknown
- 1995-10-25 SK SK542-97A patent/SK54297A3/sk unknown
- 1995-10-25 CZ CZ19971244A patent/CZ287844B6/cs not_active IP Right Cessation
- 1995-10-25 RO RO97-00825A patent/RO116042B1/ro unknown
- 1995-10-25 EP EP95936551A patent/EP0789572A1/en not_active Withdrawn
- 1995-10-25 CA CA002203663A patent/CA2203663C/en not_active Expired - Fee Related
- 1995-10-25 BR BR9509565A patent/BR9509565A/pt not_active Application Discontinuation
- 1995-10-25 FI FI971856A patent/FI971856L/fi not_active IP Right Cessation
- 1995-10-31 HR HR94.203.184.0A patent/HRP950539A2/hr not_active Application Discontinuation
- 1995-11-01 IL IL11584395A patent/IL115843A0/xx unknown
- 1995-11-01 AR AR33407595A patent/AR001765A1/es not_active Application Discontinuation
- 1995-11-02 TR TR95/01351A patent/TR199501351A2/tr unknown
- 1995-11-02 MY MYPI95003313A patent/MY113092A/en unknown
1997
- 1997-04-10 BG BG101401A patent/BG63244B1/bg unknown
- 1997-04-21 NO NO19971832A patent/NO312538B1/no not_active IP Right Cessation
- 1997-05-02 OA OA70001A patent/OA10419A/en unknown
1999
- 1999-10-18 US US09/419,590 patent/US6274599B1/en not_active Expired - Fee Related

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0076530A2 (en) *	1981-10-01	1983-04-13	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
WO1993018755A1 (en) *	1992-03-25	1993-09-30	Depomed Systems, Incorporated	Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1996014070A1 (en) *	1994-11-02	1996-05-17	Janssen Pharmaceutica N.V.	Cisapride extended release oral compositions

Also Published As

Publication number	Publication date
SK54297A3 (en)	1997-10-08
CA2203663A1 (en)	1996-05-17
AU3844795A (en)	1996-05-31
AR001765A1 (es)	1997-12-10
RU2143890C1 (ru)	2000-01-10
EE9700105A (et)	1997-12-15
CA2203663C (en)	2002-04-30
MY113092A (en)	2001-11-30
EE03510B1 (et)	2001-10-15
NO312538B1 (no)	2002-05-27
TW466114B (en)	2001-12-01
BG63244B1 (bg)	2001-07-31
CZ124497A3 (en)	1997-08-13
NO971832L (no)	1997-04-21
KR100255521B1 (ko)	2000-05-01
US6153623A (en)	2000-11-28
TR199501351A2 (tr)	1996-06-21
NO971832D0 (no)	1997-04-21
JPH09511760A (ja)	1997-11-25
BG101401A (bg)	1997-12-30
AP9700969A0 (en)	1997-04-30
PL181470B1 (pl)	2001-07-31
NZ295166A (en)	1999-03-29
FI971856A0 (fi)	1997-04-30
OA10419A (en)	2001-12-06
AU704284B2 (en)	1999-04-15
US6274599B1 (en)	2001-08-14
ZA959221B (en)	1997-04-30
CZ287844B6 (en)	2001-02-14
HUT77887A (hu)	1998-09-28
MX9703249A (es)	1997-07-31
JP3182423B2 (ja)	2001-07-03
FI971856A7 (fi)	1997-04-30
EP0789572A1 (en)	1997-08-20
FI971856L (fi)	1997-04-30
WO1996014070A1 (en)	1996-05-17
BR9509565A (pt)	1997-09-16
PL319948A1 (en)	1997-09-01
HRP950539A2 (en)	1997-08-31
RO116042B1 (ro)	2000-10-30
IL115843A0 (en)	1996-01-31
UA50721C2 (uk)	2002-11-15

Publication	Publication Date	Title
AP658A (en)	1998-08-17	Cisapride extended release oral compositions.
EP2079446B1 (en)	2011-10-26	Paliperidone sustained release formulation
RU2376988C2 (ru)	2009-12-27	Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
US8449914B2 (en)	2013-05-28	Controlled release carvedilol compositions
US20050042290A1 (en)	2005-02-24	Controlled release pharmaceutical formulation containing venlafaxine
PT85213B (pt)	1990-03-30	Processo para a preparacao de composicoes farmaceuticas de libertacao prolongada para administracao oral contendo um polimero celusosico
HUP0203334A2 (hu)	2003-02-28	Közvetlen kompresszióval előállított polimer tabletta magok
WO2007112574A1 (en)	2007-10-11	Extended release composition of venlafaxine
NZ538519A (en)	2008-05-30	Bicifadine formulation for reducing pain
KR20190089758A (ko)	2019-07-31	미라베그론 또는 이의 약제학적으로 허용가능한 염을 함유하는 지속 방출 제제
EP2101742B1 (en)	2011-05-11	Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
KR20070028598A (ko)	2007-03-12	위 체류 성질을 갖는 테디사밀의 경구용 서방성 제제
KR101811700B1 (ko)	2017-12-22	레보드로프로피진 함유 서방정 및 이의 제조방법
EP1815850B1 (en)	2008-11-26	Controlled release formulation of divalproic acid and its derivatives
CN1162263A (zh)	1997-10-15	西沙必利的缓释口服组合物
US20080008754A1 (en)	2008-01-10	Pharmaceutical Compositions Comprising (+)-(2S,3S)-2-(3-Chlorophenyl)-3,5,5-Trimethyl-2-Morpholinol
MXPA97003249A (en)	1997-12-01	Oral compositions of extended release of cisapr
AU2006335344A1 (en)	2007-07-19	Controlled release formulation of divalproic acid and its derivatives
WO2008038106A1 (en)	2008-04-03	Venlafaxine extended release formulations
US20130267560A1 (en)	2013-10-10	Sustained release pharmaceutical compositions of donepezil
US20110318413A1 (en)	2011-12-29	Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof